ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
April 25 2018 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Blaine McKee, Ph.D. has been appointed
Executive Vice President and Chief Business Officer.
“As ImmunoGen continues to evolve, we look to complement our
existing team with outside talent with experience to accelerate our
transition to a fully-integrated biotechnology company delivering
innovative products to improve outcomes for cancer patients,” said
Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.
“Blaine’s successful track record in leading strategy, corporate
development, and commercial assessment functions for premier
companies will be invaluable as we advance towards our goal of
bringing mirvetuximab soravtansine to market in 2020.”
Dr. McKee brings 25 years of experience in building
biotechnology companies and has extensive strategic, transactional,
and market access expertise. He joins ImmunoGen from Shire plc,
where he served as Head of Corporate Development, leading corporate
strategy, M&A, due diligence, commercial assessment, and
alliance management functions. Prior to joining Shire, Dr. McKee
was Executive Vice President and Chief Business Officer at 480
Biomedical, a venture capital-backed medical device company. Before
joining 480 Biomedical, he held a number of positions of increasing
responsibility at Genzyme over a 15-year tenure, most recently
serving as Senior Vice President of Strategic Development for the
Oncology, Transplant, and Multiple Sclerosis divisions.
Dr. McKee currently serves on the Board of BioStage, Inc. and
served for many years on the Board of the New York Pharma Forum. He
received a Bachelor of Science in Chemistry from Colorado State
University, a Ph.D. in Organic Chemistry from the Massachusetts
Institute of Technology (MIT), and an MBA in Finance from the MIT
Sloan School of Management.
“I am excited to join ImmunoGen during this transformational
time,” said Dr. McKee. “The Company is well-positioned to realize
its full potential by building on its leadership in ADCs with
continued innovation in oncology. I look forward to working with
the talented team at ImmunoGen to bring novel ADCs to market and
make a meaningful difference in the lives of cancer patients.”
About ImmunoGen, Inc.ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. The Company’s lead product
candidate, mirvetuximab soravtansine, is in the FORWARD I Phase 3
trial for FRα-positive platinum-resistant ovarian cancer, and is in
the FORWARD II Phase 1b/2 trial in combination regimens for
earlier-stage disease. ImmunoGen has three additional
clinical-stage product candidates, two of which are being developed
in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC
technology is also used in Roche's marketed product, Kadcyla®, and
in programs in development by Amgen, Bayer, Biotest, CytomX,
Debiopharm, Lilly, Novartis, Sanofi, and Takeda. More information
about the Company can be found at www.immunogen.com.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
and clinical studies, their timings and results. A review of these
risks can be found in ImmunoGen's Transition Report on Form 10-K
for the fiscal year ended December 31, 2017 and other
reports filed with the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180425005085/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI Consulting
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024